Thursday, July 2, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
The FDA Is Saying Yes More Often. It's Just Taking Much Longer to Get There.
Halfway through 2026, the medical device industry got a data point that cuts two ways at once. The FDA is clearing and approving more devices than it did a year ago — more premarket approvals, more panel-track supplements, more 510(k)s on pace than 2025. By the crude measure most people reach for first, the agency is more productive than it was.
Then you look at the clock.
According to a mid-year analysis of FDA’s device databases by BTIG analyst Ryan Zimmerman, the average time to an original premarket approval — the agency’s most stringent review, reserved for its highest-risk devices — stretched to roughly 599 days in the first half of 2026, up from about 402 days over the same period last year. That is nearly seven additional months of waiting for the companies whose products sit at the top of the risk pyramid. The volume is up; the wait is up more.
The number deserves a caveat, and it’s an important one. Zimmerman flagged that a handful of long-delayed approvals finally crossed the finish line in the first half — three outliers that had been stuck in the pipeline for years and dragged the average sharply upward. Strip those three out, and the average time to PMA approval falls to about 339 days, which would actually be an improvement over last year. So the headline figure is real but distorted: the typical device isn’t waiting 599 days. The system cleared a backlog, and the backlog is showing up in the math.
But the softer signals point the same direction as the scary one. The average 510(k) decision — the workhorse pathway that carries the vast majority of devices to market — slipped to about 156 days, a 5% increase over 2025. De novo classifications took roughly 8% longer. Panel-track approvals, up nearly 17% in volume, still took 6.5% longer each. Across nearly every pathway, the pattern holds: more throughput, slower clocks.
For a large diversified manufacturer, a few extra weeks or months is an annoyance to be managed. For a venture-backed company with one product and eighteen months of cash, it is the whole ballgame. Zimmerman made the point plainly: the absolute level of approvals is encouraging, but for many in the industry — and for smaller companies in particular — the timing to approval carries more weight, because it dictates capital runway and demand forecasting. An approval that arrives a quarter late can mean a bridge round raised on worse terms, a commercial launch pushed into a different budget cycle, or a sales forecast that has to be rebuilt from scratch.
The context behind the slowdown isn’t a mystery. The device center spent the past year absorbing significant staff reductions — more than 3,000 roles cut — and is now trying to hire back upward of 2,000 people. The reviewers who stayed have been carrying heavier caseloads through the transition. A center can clear more submissions and still take longer on each one when it’s running short-handed against a growing queue — that’s not a contradiction, it’s what a strained pipeline looks like from the outside.
The strategic read for device leaders is less about the exact day count than about what to assume when you build the plan. For anyone modeling a submission this year, the prudent move is to treat the review clock as a variable that has widened, not a fixed input carried over from a smoother year — and to know which pathway you’re in, because the pain isn’t evenly distributed. The 510(k) drift is modest. The high-risk PMA and de novo routes are where the timeline risk is concentrated, and those are exactly the routes the most novel, most capital-intensive products travel. The agency is saying yes more often. Planning around when it will say yes is the harder problem this year.
SPONSORED BY RŌG HEALTH
Most medical device companies don't fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.
RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.